1 Day PSO -1.61% DJIA -0.44% S&P 500 -0.27% Energy 0.25% ...

Risankizumab, guselkumab, and ustekinumab were associated with the lowest risk for progression from psoriasis to psoriatic arthritis.

Content by Public Service Company of Oklahoma. Learn how the Public Service Company of Oklahoma keeps the lights on for customers through every possible weather outcome.

Once-daily oral zasocitinib (TAK-279), an oral tyrosine kinase 2 (TYK2) inhibitor, provides a durable response in adults with moderate-to-severe plaque psoriasis (PsO), according to a study presented ...

Mar 28, 2026-- Takeda ( TSE:4502/NYSE:TAK ) today announced new data from the two pivotal Phase 3 studies of zasocitinib (TAK-279 ...

The European Medicines Agency has endorsed expanded use of Sotyktu for psoriatic arthritis, recommending approval after clinical trials showed improvement in joint symptoms.

Adding tirzepatide to ixekizumab significantly improved primary and key secondary outcomes ...

One-year Phase 3 data for ICOTYDE to be presented at AAD 2026 demonstrate lasting skin clearance and a favorable safety ...

Alumis is preparing to file its oral TYK2 inhibitor envudeucitinib as a treatment for psoriasis later this year, after a pair of positive phase 3 trials. The South San Francisco biotech said ...

Once-daily oral zasocitinib for moderate to severe plaque psoriasis demonstrated rapid and durable skin clearance and a ...

Bristol-Myers Squibb's deucravacitinib – one of the main pipeline assets in its $74 billion takeover of Celgene in 2019 – has been approved in its first market as a treatment for moderate-to-severe ...

Envudeucitinib, another allosteric TYK2 inhibitor, also achieved PASI 75 in 70-75% of patients at 16 weeks and PGA 0/1 status ...